{"schema_version":"1.0","type":"article","title":"Ivonescimab Moves Beyond Lung Cancer: Phase 3 Survival Win Against the Biliary Tract Cancer Standard","url":"https://drugnews.com.tw/articles/2026-09-04-ivonescimab-biliary-tract-cancer-harmoni-gi1-en.html","markdown_url":"https://drugnews.com.tw/articles/2026-09-04-ivonescimab-biliary-tract-cancer-harmoni-gi1-en.md","lang":"en","date":"2026-09-04","publish_at":"2026-09-04T08:00:00+08:00","updated_at":"2026-09-04","category":"商業分析系列","topic":"商業分析系列","tags":["Ivonescimab","HARMONi-GI1","biliary tract cancer","Akeso","Summit Therapeutics","durvalumab","PD-1 VEGF bispecific","Phase 3"],"summary":"Ivonescimab plus chemotherapy beat durvalumab plus chemotherapy on overall survival in the Phase 3 HARMONi-GI1 interim analysis, but the hazard ratio, median survival, curves, safety and subgroup results remain undisclosed.","key_points":[],"facts":[],"sections":["1 | Why Biliary Tract Cancer Is Difficult for More Than Its Small Patient Population","2 | What Did This Head-to-Head Trial Actually Compare?","3 | Why Might One Bispecific Antibody Differ From Combining Two Separate Drugs?","4 | Why Does Akeso Keep Choosing the Hardest Comparators?","5 | Can a Lung Cancer Drug Become a Pan-Tumor Platform?","6 | What Does the Result Mean for Akeso, Summit, and AstraZeneca?","7 | If the Full Dataset Is Strong, What Could Change in Clinical Practice?","8 | The Next Destination Is Not Applause but Five Complete Scorecards","Primary Sources","Disclaimer"],"references":[{"title":"[Akeso","source":"HARMONi-GI1 met its overall-survival primary endpoint]","date":"","url":"https://akesobio.com/en/media/akeso-news/260826/"},{"title":"[Summit Therapeutics","source":"HARMONi-GI1 topline result and single-region boundary]","date":"","url":"https://smmttx.com/news/press-releases/news-details/2026/Ivonescimab-Plus-Chemotherapy-Demonstrates-Statistically-Significant-Overall-Survival-Benefit-Compared-to-Durvalumab-Plus-Chemotherapy-in-First-Line-Advanced-Biliary-Tract-Cancer-in-Single-Region-Trial-Conducted-by-Akeso-in-China/default.aspx"},{"title":"[TOPAZ-1","source":"Durvalumab plus chemotherapy primary analysis]","date":"","url":"https://pubmed.ncbi.nlm.nih.gov/38319896/"},{"title":"[TOPAZ-1","source":"Updated overall-survival analysis]","date":"","url":"https://pubmed.ncbi.nlm.nih.gov/38823398/"},{"title":"[U.S. FDA","source":"Pembrolizumab plus chemotherapy for biliary tract cancer]","date":"","url":"https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-pembrolizumab-chemotherapy-biliary-tract-cancer"}],"images":[{"alt":"Figure 1 | A PD-1 and VEGF bispecific platform moves from lung cancer into biliary tract cancer","url":"https://drugnews.com.tw/assets/articles/ivonescimab-biliary-tract-cancer-harmoni-gi1-en/cover.png"},{"alt":"Figure 2 | HARMONi-GI1 cleared OS, PFS and ORR at the interim analysis, while five critical data gaps remain","url":"https://drugnews.com.tw/assets/articles/ivonescimab-biliary-tract-cancer-harmoni-gi1-en/figure-02.png"},{"alt":"Figure 3 | Ivonescimab combines PD-1 immune release and VEGF pathway control in one tetravalent bispecific antibody","url":"https://drugnews.com.tw/assets/articles/ivonescimab-biliary-tract-cancer-harmoni-gi1-en/figure-03.png"},{"alt":"Figure 4 | Five gates separate a positive China-only topline result from durable global clinical and commercial value","url":"https://drugnews.com.tw/assets/articles/ivonescimab-biliary-tract-cancer-harmoni-gi1-en/figure-04.png"}],"cover_image":"https://drugnews.com.tw/assets/articles/ivonescimab-biliary-tract-cancer-harmoni-gi1-en/cover.png","publisher":{"name":"Drugnews｜藥時事","url":"https://drugnews.com.tw/","profile":"https://drugnews.com.tw/brand-profile.json"},"citation":"Drugnews｜藥時事（2026-09-04）。Ivonescimab Moves Beyond Lung Cancer: Phase 3 Survival Win Against the Biliary Tract Cancer Standard。https://drugnews.com.tw/articles/2026-09-04-ivonescimab-biliary-tract-cancer-harmoni-gi1-en.html","disclaimer":"This article is intended for industry research and knowledge sharing only. It does not constitute investment, medical, fundraising, or individual stock advice.","translations":{"zh-Hant":"2026-09-04-ivonescimab-biliary-tract-cancer-harmoni-gi1.html"},"relationship":"independent_editorial","disclosure_url":"https://drugnews.com.tw/policy/"}